Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Keratinocyte Growth Factor - Promoting Thymic Reconstitution and Preventing Autoimmunity After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis

NCT01712945 is registered in ClinicalTrials.gov with Cambridge University Hospitals NHS Foundation Trust as lead sponsor.

NCT NCT01712945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01712945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Keratinocyte Growth Factor - Promoting Thymic Reconstitution and Preventing Autoimmunity After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
Lead sponsor
Cambridge University Hospitals NHS Foundation Trust
Phase
Phase 1/2
Overall status
Terminated
Start date
June 30, 2012
Completion date
October 31, 2017
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis